Современные возможности преодоления антибактериальной резистентности у грамотрицательных микроорганизмов
Современные возможности преодоления антибактериальной резистентности у грамотрицательных микроорганизмов
В.В.Кулабухов, А.Г.Чижов, А.Н.Кудрявцев. Современные возможности преодоления антибактериальной резистентности у грамотрицательных микроорганизмов. Consilium Medicum. Хирургия (Прил.). 2011; 2: 21-26.
Современные возможности преодоления антибактериальной резистентности у грамотрицательных микроорганизмов
В.В.Кулабухов, А.Г.Чижов, А.Н.Кудрявцев. Современные возможности преодоления антибактериальной резистентности у грамотрицательных микроорганизмов. Consilium Medicum. Хирургия (Прил.). 2011; 2: 21-26.
1. Troop P. Antimicrobial Resistance Strategy and Action Plan 2000; p. 23.
2. Costelloe C, Metcalfe Ch, Lovering A, Mant D. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010; 340: 2096.
3. Lara-Tejero M, Sutterwala FS, Ogura Y et al. Role of the caspase-1 inflammasome in Salmonella typhimurium pathogenesis. J Exp Med 2006; 203: 1407–12.
4. Rolli J, Loukili N, Levrand S et al. Bacterial flagellin elicits widespread innate immune defense mechanisms, apoptotic signaling, and a sepsis-like systemic inflammatory response in mice. Crit Care 2010; 14: 160.
5. Сидоренко С.В. Микроорганизмы семейства Enterobacteriaceae: клиническое значение и этиотропная терапия. Cons. Med.: Бактериальные инфекции. 2004; 6 (1): 43–6.
6. Cornelis P. Expressing genes in different Escherichia coli compartments. Curr Opin Biotech 2000; 11 (5): 450–4.
7. Ochman H, Lawrence JG, Groisman EA. Lateral gene transfer and the nature of bacterial innovation. Nature 2000; 405: 299–304.
8. Fournier PE, Vallenet D, Barbe V et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2006; 2: 7.
9. Glück Th. Transmission of Antibiotic-Resistance Genes by Bacteriophages. J Watch Infect Dis 2011; 9.
10. Wilson ME. Spread of Enterobacteriaceae with a New Resistance Gene. J Watch Infect Dis 2010; 8: 21–2.
11. Rice LB. Federal funding for the study of antimicrobial resistance innosocomial pathogens: No ESKAPE. J Infect Dis 2008; 197: 1079–81.
12. Martinez JA, Delgado E, Marti S. Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients. Intensive Care Med 2009; 35: 439–47.
13. Robotham JV, Graves N, Cookson BD et al. Screening, Isolation, and Decolonisation Strategies in the Control of Meticillin Resistant Staphylococcus aureus in Intensive Care Units. Cost Effectiveness Evaluation. BMJ 2010.
14. Яковлев С.В., Белобородов В.Б., Сидоренко С.В. и др. Анализ адекватности стартовых эмпирических режимов антибактериальной терапии при тяжелых нозокомиальных инфекциях (исследование АСЭТ). Клиническая фармакология и терапия 2006; 15: 2.
15. Shahid M, Sobia F, Singh A et al. Beta-lactams and beta-lactamaseinhibitors in current- or potential-clinical practice: a comprehensive update. Crit Rev Microbiol 2009; 35: 81–108.
16. Queenan AM, Shang W, Kania M et al. Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. Antimicrob Agents Chemother 2007; 51: 3089–95.
17. Sader HS, Fritsche TR, Kaniga K et al. Antimicrobial activity and spectrum of ppi-0903m (t-91825), a novel cephalosporin, tested against a worldwide collection of clinical strain. Antimicrob Agents Chemother 2005; 49: 3501–12.
18. Bassetti M, Nicolini L, Esposito S. Current status of newer arbapenems. Curr Med Chem 2009; 16: 564–75.
19. Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 2005; 65: 2151–78.
20. Borbone S. Bactericidal activity of ertapenem against majority intraabdominal pathogens. Int J of Antimicrobial Agents 2006; 28 (5): 396–401.
21. Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (s-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004; 48: 3136–40.
22. Sato N, Kijima K, Koresawa T et al. Population pharmacokinetics of tebipenempivoxil (me1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia. Drug Metabol and Pharmacokinet 2008; 23: 434–46.
23. Arnold RS, Thom KA, Sharma S. Emergence of Klebsiella pneumoniae Carbapenemase-producing Bacteria. South Med J 2011; 104 (1); 40–5.
24. Glück T. Combination Antibiotic Therapy for Severe Sepsis, Revisited. J Watch Infect Dis 2010; 10.
Авторы
В.В.Кулабухов, А.Г.Чижов, А.Н.Кудрявцев
Институт хирургии им. А.В.Вишневского Минздравсоцразвития РФ, Москва